Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes

Tunghi M. Pini, Marie R. Griffin, Christianne L. Roumie, Mary Margaret Huizinga, Jay Fowke, Robert Greevy, Xulei Liu, Harvey J. Murff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thiazolidinediones (TZD) have been shown to down-regulate prostate-specific antigen (PSA) levels in prostate cancer cell lines and decrease PSA velocity among prostate cancer patients; however, the effect of TZDs on serum PSA levels among men with diabetes at risk for prostate cancer is unknown. We conducted a retrospective cohort study of veterans receiving care for diabetes between 1999 and 2005 to determine if TZD use affects PSA levels in veterans at risk for prostate cancer. Eligible patients were male, ≥45 years old, taking at least one oral antidiabetic medication, and with two or more recorded PSA values. Patients with a prior history of prostate cancer or prostatectomy were excluded. Of the 13,791 patients included in the adjusted analysis, 2,016 (14.6%) were prescribed a TZD. No effect of cumulative TZD dose on change in PSA was detected (P = 0.26). Increased TZD exposure was not associated with a change in PSA, suggesting that TZD treatment for diabetes is unlikely to affect prostate cancer detection.

Original languageEnglish (US)
Pages (from-to)1937-1938
Number of pages2
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2009

Fingerprint

Thiazolidinediones
Prostate-Specific Antigen
Prostatic Neoplasms
Veterans
Prostatectomy
Hypoglycemic Agents
Cohort Studies
Down-Regulation
Retrospective Studies
Cell Line
Serum

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes. / Pini, Tunghi M.; Griffin, Marie R.; Roumie, Christianne L.; Huizinga, Mary Margaret; Fowke, Jay; Greevy, Robert; Liu, Xulei; Murff, Harvey J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 6, 01.06.2009, p. 1937-1938.

Research output: Contribution to journalArticle

Pini, Tunghi M. ; Griffin, Marie R. ; Roumie, Christianne L. ; Huizinga, Mary Margaret ; Fowke, Jay ; Greevy, Robert ; Liu, Xulei ; Murff, Harvey J. / Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes. In: Cancer Epidemiology Biomarkers and Prevention. 2009 ; Vol. 18, No. 6. pp. 1937-1938.
@article{122efba4e1454440a5d8bdc9e41ec379,
title = "Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes",
abstract = "Thiazolidinediones (TZD) have been shown to down-regulate prostate-specific antigen (PSA) levels in prostate cancer cell lines and decrease PSA velocity among prostate cancer patients; however, the effect of TZDs on serum PSA levels among men with diabetes at risk for prostate cancer is unknown. We conducted a retrospective cohort study of veterans receiving care for diabetes between 1999 and 2005 to determine if TZD use affects PSA levels in veterans at risk for prostate cancer. Eligible patients were male, ≥45 years old, taking at least one oral antidiabetic medication, and with two or more recorded PSA values. Patients with a prior history of prostate cancer or prostatectomy were excluded. Of the 13,791 patients included in the adjusted analysis, 2,016 (14.6{\%}) were prescribed a TZD. No effect of cumulative TZD dose on change in PSA was detected (P = 0.26). Increased TZD exposure was not associated with a change in PSA, suggesting that TZD treatment for diabetes is unlikely to affect prostate cancer detection.",
author = "Pini, {Tunghi M.} and Griffin, {Marie R.} and Roumie, {Christianne L.} and Huizinga, {Mary Margaret} and Jay Fowke and Robert Greevy and Xulei Liu and Murff, {Harvey J.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1158/1055-9965.EPI-09-0215",
language = "English (US)",
volume = "18",
pages = "1937--1938",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes

AU - Pini, Tunghi M.

AU - Griffin, Marie R.

AU - Roumie, Christianne L.

AU - Huizinga, Mary Margaret

AU - Fowke, Jay

AU - Greevy, Robert

AU - Liu, Xulei

AU - Murff, Harvey J.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Thiazolidinediones (TZD) have been shown to down-regulate prostate-specific antigen (PSA) levels in prostate cancer cell lines and decrease PSA velocity among prostate cancer patients; however, the effect of TZDs on serum PSA levels among men with diabetes at risk for prostate cancer is unknown. We conducted a retrospective cohort study of veterans receiving care for diabetes between 1999 and 2005 to determine if TZD use affects PSA levels in veterans at risk for prostate cancer. Eligible patients were male, ≥45 years old, taking at least one oral antidiabetic medication, and with two or more recorded PSA values. Patients with a prior history of prostate cancer or prostatectomy were excluded. Of the 13,791 patients included in the adjusted analysis, 2,016 (14.6%) were prescribed a TZD. No effect of cumulative TZD dose on change in PSA was detected (P = 0.26). Increased TZD exposure was not associated with a change in PSA, suggesting that TZD treatment for diabetes is unlikely to affect prostate cancer detection.

AB - Thiazolidinediones (TZD) have been shown to down-regulate prostate-specific antigen (PSA) levels in prostate cancer cell lines and decrease PSA velocity among prostate cancer patients; however, the effect of TZDs on serum PSA levels among men with diabetes at risk for prostate cancer is unknown. We conducted a retrospective cohort study of veterans receiving care for diabetes between 1999 and 2005 to determine if TZD use affects PSA levels in veterans at risk for prostate cancer. Eligible patients were male, ≥45 years old, taking at least one oral antidiabetic medication, and with two or more recorded PSA values. Patients with a prior history of prostate cancer or prostatectomy were excluded. Of the 13,791 patients included in the adjusted analysis, 2,016 (14.6%) were prescribed a TZD. No effect of cumulative TZD dose on change in PSA was detected (P = 0.26). Increased TZD exposure was not associated with a change in PSA, suggesting that TZD treatment for diabetes is unlikely to affect prostate cancer detection.

UR - http://www.scopus.com/inward/record.url?scp=67449085153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449085153&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-0215

DO - 10.1158/1055-9965.EPI-09-0215

M3 - Article

VL - 18

SP - 1937

EP - 1938

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -